Centauri Therapeutics Overview

  • Founded

  • 2014

Founded
  • Status

  • Private

  • Employees

  • 7

Employees
  • Latest Deal Type

  • Series A

  • Latest Deal Amount

  • $32.5M

  • Investors

  • 9

Centauri Therapeutics General Information

Description

Operator of a biotechnology company intended to discover and develop novel molecules and immunotherapy targeting life-threatening diseases. The company uses alphamer technology, in which chemically synthesized molecules redirect naturally occurring antibodies to selected pathogens to fight infections, enabling doctors to treat infectious diseases efficiently.

Contact Information

Website
www.centauritherapeutics.com
Formerly Known As
Altermet, Altermune
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Discovery Park
  • Kent CT13 9ND
  • England, United Kingdom
+44 01304 000000

Centauri Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Centauri Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A) 16-Feb-2022 $32.5M 000.00 Completed Generating Revenue
5. Later Stage VC 14-Aug-2020 00000 00.00 000.00 Completed Generating Revenue
4. Early Stage VC 01-Dec-2018 00.000 00.000 000.00 Completed Generating Revenue
3. Accelerator/Incubator 11-Sep-2017 00.000 00.000 Completed Generating Revenue
2. Early Stage VC 20-Feb-2017 $3.13M $6.11M Completed Generating Revenue
1. Early Stage VC 21-Dec-2016 $2.99M $2.99M 000.00 Completed Startup
To view Centauri Therapeutics’s complete valuation and funding history, request access »

Centauri Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary 0,000 00.000000 0000.00 0000.00 0000.00 0.000
Ordinary 0,000 00.000000 0000.00 0000.00 0000.00 0.000
Ordinary 000 00.000000 0000.00 0000.00 0000.00 0.00
Ordinary 0,000 00.000000 0000.00 0000.00 0000.00 0.00
Ordinary 0,000 00.000000 0000.00 0000.00 0000.00 00.000
Ordinary 000 00.000000 0000.00 0000.00 0000.00 0.000
Ordinary 00 00.000000 0000.00 0000.00 0000.00 0.000
Ordinary 000 00.000000 0000.00 0000.00 0000.00 0.000
Ordinary 621 $0.003110 $311.57 $311.57 $311.57 1.04%
Ordinary 311 $0.003110 $311.07 $311.07 $311.07 0.52%
To view Centauri Therapeutics’s complete cap table history, request access »

Centauri Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biotechnology company intended to discover and develop novel molecules and immunotherapy targeting life-th
Drug Discovery
Kent, United Kingdom
7 As of 2022
000.00
00000000000 000.00

00000

dipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
0000 000000000
Geneva, Switzerland
00 As of 0000
00000
00000000000 00000

000000

esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt i
0000 000000000
Vienna, Austria
00.000
0000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Centauri Therapeutics Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Light Chain Bioscience Private Equity-Backed Geneva, Switzerland 00 00000 00000000000 00000
00000000 Venture Capital-Backed Vienna, Austria 00.000 0000000000 00.000
0000000 0000000000 Formerly VC-backed Boston, MA 0 00000 000000000 00000
0000000 Venture Capital-Backed Oxford, United Kingdom 00 00000 00000000000 00000
000000 Venture Capital-Backed Cambridge, United Kingdom 00 00000 00000000000 00000
You’re viewing 5 of 21 competitors. Get the full list »

Centauri Therapeutics Patents

  • 53

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 5

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

Centauri Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201804098-D0 Novel compounds and therapeutic uses thereof Ceased 14-Mar-2018 000000000
AU-2019233810-A1 Immunity linker molecules and their use in the treatment of infectious diseases Pending 14-Mar-2018 0000000000
EP-3765155-A1 Immunity linker molecules and their use in the treatment of infectious diseases Pending 14-Mar-2018 0000000000
US-20210085798-A1 Immunity linker molecules and their use in the treatment of infectious diseases Pending 14-Mar-2018 0000000000
GB-201707079-D0 Novel compounds and therapeutics uses thereof Ceased 04-May-2017 A61K38/12
To view Centauri Therapeutics’s complete patent history, request access »

Centauri Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Michael Westby Ph.D Chief Scientific Officer & Board Member
Stuart Lawson Co-Founder, Chief Financial Officer & Board Member
To view Centauri Therapeutics’s complete executive team members history, request access »

Centauri Therapeutics Board Members (8)

Name Representing Role Since
Camilla Hansen Ph.D Novo Holdings Board Member 000 0000
Johannes Zanzinger Ph.D Boehringer Ingelheim Venture Fund Board Member 000 0000
Jonathan Synett NCL Technology Ventures Board Member 000 0000
Karen Lackey Evotec Board Member 000 0000
Michael Westby Ph.D Centauri Therapeutics Chief Scientific Officer & Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Centauri Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Centauri Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Boehringer Ingelheim Venture Fund Venture Capital Minority 000 0000 000000 0
Evotec Corporation Minority 000 0000 000000 0
Novo Holdings Venture Capital Minority 000 0000 000000 0
Wren Capital Angel Group Minority 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Centauri Therapeutics Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 02-Mar-2016 00000 0000 00000 Drug Discovery 0000000 0
Altermune Technologies 18-Jan-2016 Buyout/LBO Drug Discovery 0000000 0
To view Centauri Therapeutics’s complete investments history, request access »

Ready to get started?

Request a free trial